218 related articles for article (PubMed ID: 19558722)
21. Clinical monitoring and management of complications related to chelation therapy in patients with β-thalassemia.
Saliba AN; El Rassi F; Taher AT
Expert Rev Hematol; 2016; 9(2):151-68. PubMed ID: 26613264
[TBL] [Abstract][Full Text] [Related]
22. Four-year evaluation of myocardial and liver iron assessed prospectively with serial MRI scans in young patients with beta-thalassaemia major: comparison between different chelation regimens.
Christoforidis A; Haritandi A; Tsatra I; Tsitourides I; Karyda S; Athanassiou-Metaxa M
Eur J Haematol; 2007 Jan; 78(1):52-7. PubMed ID: 17042760
[TBL] [Abstract][Full Text] [Related]
23. Effective new treatments of iron overload in thalassaemia using the ICOC combination therapy protocol of deferiprone (L1) and deferoxamine and of new chelating drugs.
Kontoghiorghes GJ; Kolnagou A
Haematologica; 2006 Jun; 91(6 Suppl):ELT04. PubMed ID: 16785141
[TBL] [Abstract][Full Text] [Related]
24. Effects of combined deferiprone and deferoxamine chelation therapy on iron load indices in beta-thalassemia.
Tsironi M; Assimakopoulos G; Polonofi K; Rigaki K; Aessopos A
Hemoglobin; 2008; 32(1-2):29-34. PubMed ID: 18274980
[TBL] [Abstract][Full Text] [Related]
25. Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions.
Neufeld EJ
Blood; 2006 May; 107(9):3436-41. PubMed ID: 16627763
[TBL] [Abstract][Full Text] [Related]
26. Reduction of body iron stores to normal range levels in thalassaemia by using a deferiprone/deferoxamine combination and their maintenance thereafter by deferiprone monotherapy.
Kolnagou A; Kleanthous M; Kontoghiorghes GJ
Eur J Haematol; 2010 Nov; 85(5):430-8. PubMed ID: 20662901
[TBL] [Abstract][Full Text] [Related]
27. Potential myocardial iron content evaluation by magnetic resonance imaging in thalassemia major patients treated with Deferoxamine or Deferiprone during a randomized multicenter prospective clinical study.
Galia M; Midiri M; Bartolotta V; Morabito A; Rizzo M; Mangiagli A; Malizia R; Borsellino Z; Capra M; D'Ascola DG; Magnano C; Gerardi C; Rigano P; Maggio A;
Hemoglobin; 2003 May; 27(2):63-76. PubMed ID: 12779268
[TBL] [Abstract][Full Text] [Related]
28. Comparative efficacy and safety of deferoxamine, deferiprone and deferasirox on severe thalassemia: a meta-analysis of 16 randomized controlled trials.
Xia S; Zhang W; Huang L; Jiang H
PLoS One; 2013; 8(12):e82662. PubMed ID: 24376563
[TBL] [Abstract][Full Text] [Related]
29. Deferiprone: a review of its clinical potential in iron overload in beta-thalassaemia major and other transfusion-dependent diseases.
Barman Balfour JA; Foster RH
Drugs; 1999 Sep; 58(3):553-78. PubMed ID: 10493280
[TBL] [Abstract][Full Text] [Related]
30. Chromosomal aberration frequencies in patients with thalassaemia major undergoing therapy with deferiprone and deferoxamine in a comparative crossover study.
Marshall R; Tricta F; Galanello R; Leoni G; Kirkland D; Minto S; Spino M
Mutagenesis; 2003 Sep; 18(5):457-63. PubMed ID: 12960415
[TBL] [Abstract][Full Text] [Related]
31. Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major.
Farmaki K; Tzoumari I; Pappa C; Chouliaras G; Berdoukas V
Br J Haematol; 2010 Feb; 148(3):466-75. PubMed ID: 19912219
[TBL] [Abstract][Full Text] [Related]
32. Efficacy, compliance and toxicity factors are affecting the rate of normalization of body iron stores in thalassemia patients using the deferiprone and deferoxamine combination therapy.
Kolnagou A; Kleanthous M; Kontoghiorghes GJ
Hemoglobin; 2011; 35(3):186-98. PubMed ID: 21599431
[TBL] [Abstract][Full Text] [Related]
33. Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility.
Kontoghiorghes GJ; Kolnagou A
Lancet; 2003 Jan; 361(9352):184. PubMed ID: 12531621
[No Abstract] [Full Text] [Related]
34. Cardiac iron removal and functional cardiac improvement by different iron chelation regimens in thalassemia major patients.
Cassinerio E; Roghi A; Pedrotti P; Brevi F; Zanaboni L; Graziadei G; Pattoneri P; Milazzo A; Cappellini MD
Ann Hematol; 2012 Sep; 91(9):1443-9. PubMed ID: 22572843
[TBL] [Abstract][Full Text] [Related]
35. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis.
Pennell DJ; Berdoukas V; Karagiorga M; Ladis V; Piga A; Aessopos A; Gotsis ED; Tanner MA; Smith GC; Westwood MA; Wonke B; Galanello R
Blood; 2006 May; 107(9):3738-44. PubMed ID: 16352815
[TBL] [Abstract][Full Text] [Related]
36. Therapeutic efficacy of different iron chelators in Egyptian children with Beta Thalassemia with iron overload.
Hagag AA; Hamam MA; Taha OA; Hazaa SM
Infect Disord Drug Targets; 2015; 15(2):98-105. PubMed ID: 26205801
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients.
Elalfy MS; Adly AM; Wali Y; Tony S; Samir A; Elhenawy YI
Eur J Haematol; 2015 Nov; 95(5):411-20. PubMed ID: 25600572
[TBL] [Abstract][Full Text] [Related]
38. Effect of deferiprone or deferoxamine on right ventricular function in thalassemia major patients with myocardial iron overload.
Smith GC; Alpendurada F; Carpenter JP; Alam MH; Berdoukas V; Karagiorga M; Ladis V; Piga A; Aessopos A; Gotsis ED; Tanner MA; Westwood MA; Galanello R; Roughton M; Pennell DJ
J Cardiovasc Magn Reson; 2011 Jul; 13(1):34. PubMed ID: 21733147
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes.
Kontoghiorghe CN; Kontoghiorghes GJ
Drug Des Devel Ther; 2016; 10():465-81. PubMed ID: 26893541
[TBL] [Abstract][Full Text] [Related]
40. Timed non-transferrin bound iron determinations probe the origin of chelatable iron pools during deferiprone regimens and predict chelation response.
Aydinok Y; Evans P; Manz CY; Porter JB
Haematologica; 2012 Jun; 97(6):835-41. PubMed ID: 22180427
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
